NasdaqCM - Nasdaq Real Time Price USD

TNF Pharmaceuticals, Inc. (TNFA)

0.1900
-0.0066
(-3.36%)
At close: May 9 at 4:00:02 PM EDT
0.1835
-0.01
(-3.42%)
After hours: May 9 at 7:44:12 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expense
8,660.1880
8,660.1880
16,360.2180
15,282.7630
28,201.2470
Operating Income
-8,660.1880
-8,660.1880
-16,360.2180
-15,282.7630
-28,201.2470
Net Non Operating Interest Income Expense
351.8090
351.8090
455.5700
83.9910
-599.5530
Other Income Expense
-15,050.9550
-15,050.9550
11,904.6980
1.4360
-1,088.2450
Pretax Income
-23,359.3340
-23,359.3340
-3,999.9500
-15,197.3360
-29,889.0450
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-27,161.2190
-27,161.2190
-8,218.1630
-15,197.3360
-29,889.0450
Diluted NI Available to Com Stockholders
-27,161.2190
-27,161.2190
-8,218.1630
-15,197.3360
-29,889.0450
Basic EPS
-11.15
--
-5.33
-11.74
-25.50
Diluted EPS
-11.15
--
-5.33
-11.74
-25.50
Basic Average Shares
2,437
--
1,542.4530
1,294.1990
1,167.2410
Diluted Average Shares
2,437
--
1,542.4530
1,294.1990
1,167.2410
Total Operating Income as Reported
-10,168.7900
-10,168.7900
-17,123.0520
-15,282.7630
-28,809.7070
Total Expenses
8,660.1880
8,660.1880
16,360.2180
15,282.7630
28,201.2470
Net Income from Continuing & Discontinued Operation
-23,359.3340
-23,359.3340
-3,999.9500
-15,197.3360
-29,889.0450
Normalized Income
-18,662.9810
-18,662.9810
-16,667.4820
-15,198.7720
-28,800.8000
Interest Income
351.8090
351.8090
455.5700
83.9910
8.9070
Interest Expense
-92.6300
--
--
0
608.4600
Net Interest Income
351.8090
351.8090
455.5700
83.9910
-599.5530
EBIT
-8,660.1880
-8,660.1880
-16,360.2180
-15,282.7630
-29,280.5850
EBITDA
-8,660.1880
-8,660.1880
-16,360.2180
-15,282.7630
-29,280.5850
Reconciled Cost of Revenue
0
0
0
0
0
Reconciled Depreciation
--
--
--
--
0
Net Income from Continuing Operation Net Minority Interest
-23,359.3340
-23,359.3340
-3,999.9500
-15,197.3360
-29,889.0450
Total Unusual Items Excluding Goodwill
-4,696.3530
-4,696.3530
12,667.5320
1.4360
-1,088.2450
Total Unusual Items
-4,696.3530
-4,696.3530
12,667.5320
1.4360
-1,088.2450
Normalized EBITDA
-3,963.8350
-3,963.8350
-29,027.7500
-15,284.1990
-28,192.3400
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/23/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCSA Processa Pharmaceuticals, Inc.
0.2390
-12.77%
 
ONCO Onconetix, Inc.
0.0720
-1.10%
 
PTIX Protagenic Therapeutics, Inc.
3.1100
-11.14%
 
ALLR Allarity Therapeutics, Inc.
1.0500
-1.87%
 
HEPA Hepion Pharmaceuticals, Inc.
0.3916
-0.61%
 
MTVA MetaVia Inc.
0.7290
+3.21%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.2534
-15.53%
 
GRI GRI Bio, Inc.
1.4700
-8.12%
 
AZTR Azitra, Inc.
0.2950
-0.97%
 
LYRA Lyra Therapeutics, Inc.
0.0982
+4.03%